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Background: Despite increasing incidence of hepatocellular carcinoma (HCC) among 
HIV-infected patients, it remains unclear if HIV-related factors contribute to 
development of HCC. We examined if higher or prolonged HIV viremia and lower CD4+
cell percentage were associated with HCC.
Methods: We conducted a cohort study of HIV-infected individuals who had HIV RNA,
CD4+, and CD8+ cell counts and percentages assessed in the Veterans Aging Cohort 
Study (1999-2015). HCC was ascertained using Veterans Health Administration 
cancer registries and electronic records. Cox regression was used to determine 
hazard ratios (HR [95% confidence interval]) of HCC associated with higher current 
HIV RNA, longer duration of detectable HIV viremia (≥500 copies/mL), and current 
CD4+ cell percentage <14%, adjusting for traditional HCC risk factors. Analyses were 
stratified by previously validated diagnoses of cirrhosis prior to start of follow-up.
Results: Among 35,659 HIV-infected patients, 302 (0.8%) developed HCC over 
281,441 person-years (incidence rate, 107.3/100,000 person-years). Among 
patients without baseline cirrhosis, higher HIV RNA (1.25 [1.12-1.40] per 1.0 log10 
copies/mL) and ≥12 months of detectable HIV (1.47 [1.02-2.11]) were 
independently associated with higher risk of HCC. CD4+ percentage <14% was not 
associated with HCC in any model. Hepatitis B and C coinfection were each 
significant predictors of HCC regardless of baseline cirrhosis status.
Conclusion: Among HIV-infected patients without baseline cirrhosis, higher HIV 



























traditional HCC risk factors. This is the strongest evidence to date that HIV viremia 






Hepatocellular carcinoma (HCC) is a growing cause of cancer death among 
people living with HIV infection.1 Driven largely by hepatitis C virus (HCV) coinfection, 
hepatitis B virus (HBV) coinfection, and alcoholic liver disease, the incidence of HCC 
among HIV-infected persons in North America has risen more than 4-fold from 1995-
2009.2 Moreover, HIV-infected individuals have a 4-fold higher risk of HCC than 
uninfected persons.3
Despite the rising incidence of HCC among HIV-infected individuals, the 
determinants of this malignancy remain largely unknown in this group.4 Three prior 
studies found no association between HIV suppression and risk of HCC,5-7 but these 
studies did not evaluate the effects of longer durations or higher levels of HIV viremia, 
nor did they account for cirrhosis. Moreover, previous studies among predominantly 
HIV/HCV-coinfected patients reported that lower absolute CD4+ cell counts increased 
the risk of HCC.6,8-12 However, absolute CD4+ cell count may decrease during cirrhosis 
due to portal hypertension-induced splenic sequestration.13 Thus, studies evaluating 
associations between absolute CD4+ cell count and HCC risk cannot determine 
whether observed associations are driven by HIV-related immunosuppression or 
progression of liver disease. Consequently, it remains unclear if higher HIV RNA levels,
longer duration of detectable HIV, and HIV-related immunosuppression contribute to 
development of HCC independent of traditional determinants. Identifying such factors 
could help define the mechanisms for the high rate of HCC among HIV-infected 
persons. 
Cirrhosis, which represents the late stage of progressive hepatic fibrosis due 
to chronic liver disease, is an important step in the causal pathway towards HCC 



























of the liver milieu (e.g., increased production of toxic hepatic metabolites, 
cytokines, growth factors, and products of oxidative stress).15 Since cirrhosis 
increases the risk of HCC substantially, studies evaluating the factors associated 
with HCC must account for baseline cirrhosis status.
We evaluated HIV-related and traditional risk factors for HCC among HIV-
infected patients. We hypothesized that higher HIV RNA levels, longer duration of 
HIV viremia, and lower CD4+ cell percentage, which is not affected by liver disease 
progression,13 were significant determinants of HCC. We also examined the risk of 
HCC with traditional risk factors in the general population, including older age, black
race, overweight/obesity, diabetes mellitus, alcohol dependence/abuse, tobacco 
use, and HBV and HCV coinfection.16 To account for the role of cirrhosis in the 
development of HCC and the possibility that risk factors for HCC might vary by 
presence of cirrhosis, we stratified our analysis by baseline cirrhosis status.
METHODS
Study Design and Data Source
We conducted a retrospective cohort study among HIV-infected individuals in 
the Veterans Aging Cohort Study (VACS) between October 1, 1999 and September 30,
2015.17 The VACS consists of electronic medical record data from HIV-infected 
patients receiving care at Veterans Health Administration (VA) facilities across the 
United States (US). Data include demographics, hospital and outpatient diagnoses 
(recorded using International Classification of Diseases, Ninth Revision [ICD-9] codes),
procedures, laboratory results, and dispensed medications. Death date was 
determined from the VA Vital Status File. The study was approved by the Institutional 



























Medical Center in Philadelphia, VA Connecticut Healthcare System, and Yale 
University.
Study Patients
HIV-infected patients were included if they had: 1) HIV RNA, CD4+, and CD8+ 
count/percentage simultaneously assessed (which occurs routinely as part of HIV care
in the VA system) between October 1, 1999 and September 30, 2015, and 2) at least 
180 days of observation after determination of these laboratory results. We defined 
the start of follow-up as 180 days after the date that HIV RNA, CD4+, and CD8+ 
results were assessed. The 180 days prior to start of follow-up represented the 
baseline period, during which baseline comorbidities and laboratory results were 
collected. Patients were excluded if they had HCC diagnosed prior to start of follow-
up. Follow-up continued until HCC, death, or last VA visit before September 30, 2015.
Main Study Outcomes
The primary outcome was incident HCC diagnosis. HCC diagnoses were 
determined from the VA national cancer registry by topography code C22.0 (liver) and 
morphology codes 8170-8180 (HCC) from the International Classification of Diseases 
for Oncology, Third Edition (ICD-O-3),18 consistent with Surveillance, Epidemiology, and 
End Results coding algorithms.19 The VA cancer registry records cancers diagnosed 
and/or treated within the VA.7 ICD-O-3 codes validly identify cancer diagnoses, 
including HCC.20 To account for lags in reporting diagnoses in the cancer registry and 
minimize the likelihood of missing HCC events, we supplemented HCC case finding with
ICD-9 diagnoses for HCC (155.0, 155.1, and 155.2) recorded in the VA electronic 



























and ICD-9 diagnoses have 90% sensitivity for incident cancer diagnosis when 
compared to chart review; however, positive predictive value varied (96% for VA 
cancer registry; 63% for ICD-9 diagnosis).20,21 Consequently, HCC diagnoses from the 
registry and claims were confirmed by medical record review by trained adjudicators. 
For all confirmed HCC cases, we determined the presence of cirrhosis by review of 
medical records within one year prior to HCC diagnosis. Details on cirrhosis 
adjudication appear in Appendix 1.
Data Collection
Baseline data included: age; sex; race/ethnicity; body mass index (BMI); 
diabetes (defined by random glucose 200 mg/dL, hemoglobin A1c ≥6.5%, or anti-
diabetic drug use22); alcohol dependence/abuse; injection/non-injection drug use; 
tobacco use (ever); HBV coinfection (ever positive HBV surface antigen); HCV 
coinfection (ever detectable HCV RNA or genotype); cirrhosis; HIV RNA; absolute 
CD4+ and CD8+ counts and percentages; and antiretroviral therapy (ART) use. 
Cirrhosis was defined by a hospital discharge diagnosis or outpatient diagnosis for 
cirrhosis or hepatic decompensation (Appendix 2). Prior studies validated this 
determination within the VA system, with ≥90% of these diagnoses confirmed by 
medical records.23,24 Alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), and platelet count were collected from dates closest, but within 360 days 
prior, to start of follow-up. FIB-4, a non-invasive measure of hepatic fibrosis, was 
calculated by: (age [years] x AST [U/L])/(platelet count [109/L]) x (ALT [U/L])1/2).25
Time-varying variables were assessed on a monthly basis and included HIV 
RNA, CD4+ and CD8+ counts/percentages, and diabetes. When multiple results of the 



























the highest HIV RNA and CD8+ result, and lowest CD4+ result. When a test was not 
updated during a month, we carried forward the value from the previous month until 
the next available result. HIV RNA, CD4+, and CD8+ results were updated at the 
beginning of each 30-day interval from baseline but were lagged by 180 days 
(approximate mean doubling time of HCC tumors <5 centimeters in length26) to 
reduce the possibility that the presence of HCC influenced these variables (i.e., 
reverse causality).
Statistical Analysis
We determined unadjusted incidence rates (IR) of HCC (events/100,000 
person-years), overall and by HBV and HCV status. We used multivariable Cox 
regression to determine adjusted hazard ratios (HR [95% confidence interval]) of HCC
for risk factors of interest. HIV-related factors included higher time-updated HIV RNA 
level, longer duration of detectable HIV (≥500 copies/mL), and lower time-updated 
CD4+ percentage. Traditional HCC risk factors examined included older age, black 
race, overweight/obesity, diabetes, alcohol dependence/abuse, ever use of tobacco, 
HBV coinfection, and HCV coinfection.16 Given the importance of cirrhosis on 
development of HCC, analyses were stratified by baseline cirrhosis status.
To evaluate the effects of HIV viremia on HCC risk, we created four separate 
models that examined HIV as a time-updated: 1) continuous variable by 1.0 log10 
increments (model #1), 2) categorical variable defined by detectable HIV (≥500 
copies/mL; model #2), 3) categorical variable classified by increasing categories of 
HIV RNA (<500 copies/mL; 500-9,999 copies/mL; ≥10,000 copies/mL; model #3), 
and 4) categorical variable classified by increasing consecutive months of 



























#4, detectable HIV was evaluated as a monthly time-updated variable. Once a 
patient was classified with HIV viremia, consecutive months were counted until a 
viral load <500 copies/mL was identified. If detectable HIV recurred, the count of 
consecutive months of viremia was restarted at one month. We determined HRs of 
HCC associated with increasing consecutive months of detectable HIV (1-11 months;
≥12 months) compared to persons whose HIV RNA was suppressed throughout 
follow-up, adjusting for all other risk factors.
We performed five sensitivity analyses to assess the robustness of our 
results. First, we repeated the analysis accounting for competing risk of death.27 
Second, we repeated analyses, lagging HIV RNA and CD4+ cell percentages by 360 
and 540 days. Third, we evaluated risk factors for HCC separately among persons 
with HBV coinfection, HCV coinfection, and without viral hepatitis. Fourth, to explore
the potential impact of hepatic steatosis on HCC risk, we classified patients with 
possible fatty liver disease prior to start of follow-up based on the presence of both 
obesity (BMI ≥30 kg/m2) and diabetes mellitus, since these act synergistically to 
promote steatosis,28 and examined associations with HCC. Fifth, since duration of 
HIV-related immunosuppression might affect HCC risk, we determined whether 
longer consecutive months with CD4+ percentage <14% increased risk of HCC. 
Finally, in an exploratory analysis, we examined the risk of HCC with lower time-
updated CD4+/CD8+ ratio, which indicates dysfunctional immune activation,29 by 
cirrhosis status.
Proportionality of hazards was assessed by log-log plots and Schoenfeld 
residuals.30 To address the potential bias of missing data among covariates, we 
implemented multiple imputation using chained equations by means of 10 



























combined to arrive at confidence intervals that accounted for within- and across-
dataset variances. Data were analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC).
RESULTS 
Patient Characteristics
We identified 37,946 HIV-infected individuals in the VACS who had HIV RNA, 
CD4+, and CD8+ results measured simultaneously between October 1, 1999 and 
September 30, 2015. After exclusions, 35,659 remained in the final sample.
Patients in the cohort had a median age of 46 years at baseline and were 
predominantly male, black, and overweight/obese (Table 1). Tobacco use, alcohol 
dependence/abuse, and injection/non-injection drug use were common. At the start of 
follow-up, 56.7% had HIV RNA ≥500 copies/mL, 23.9% had CD4+ percentage <14%, 
and 88.5% had a CD4+/CD8+ ratio <1.0. A total of 31.9% had HCV coinfection, and 
5.6% were HBV-coinfected. Only 11.9% of HCV-coinfected persons received anti-HCV 
therapy at baseline or during follow-up.
Overall, 68.7% received ART during the baseline period. ART regimens 
prescribed reflected the antiretrovirals used at the time of study entry (Table 1). 
Among 1,981 HBV-coinfected individuals, 1,211 (61.1%) were on ART at baseline. Of 
these, 689 (56.9%) received HBV-active ART with lamivudine or emtricitabine alone, 
374 (30.9%) with tenofovir plus emtricitabine or lamivudine, and 27 (2.2%) with 
tenofovir alone; 121 (10.0%) were on ART without an HBV-active antiretroviral. By the
end of follow-up, 1,840 (92.9%) received HBV-active ART.
A total of 773 (2.2%) patients had a baseline diagnosis of cirrhosis. These 
patients were older and more commonly had diabetes, alcohol dependence/abuse, 




























Incidence Rates of HCC
Overall, 302 medical record-confirmed HCC diagnoses were identified over 
281,441 person-years (IR, 107.3/100,000 person-years) with median duration of follow-
up of 7.4 (interquartile range, 3.3-12.8) years. Rates were particularly high among the 
1,981 HBV-coinfected (IR, 350.4/100,000 person-years) and 11,392 HCV-coinfected (IR, 
224.6/100,000 person-years) individuals. 
Patients diagnosed with HCC had a high prevalence of HCV coinfection 
(82.8%), alcohol dependence/abuse (63.2%), overweight/obesity (47.7%), and HBV 
coinfection (18.9%; Table 2). Notably, 99 (32.8%) did not have cirrhosis at HCC 
diagnosis (Table 2).
Determinants of HCC, by Baseline Cirrhosis Status
Among individuals without baseline cirrhosis, higher HIV RNA in model #1 
(1.25 [1.12-1.40] per 1.0 log10 copies/mL increase), detectable HIV in model #2 (1.46
[1.07-1.99]), HIV RNA ≥10,000 copies/mL in model #3 (1.63 [1.11-2.40]), and ≥12 
months of detectable HIV viremia in model #4 (1.47 [1.02-2.11]) increased the risk 
of HCC (Table 3). Absolute CD4+ counts <200 cells/mm3 increased HCC risk 
(Appendix 3); however, lower CD4+ percentage was not associated with an 
increased risk of HCC (Table 3). Additionally, in all models, older age, diabetes, HBV 
coinfection, HCV coinfection, history of alcohol dependence/abuse, and ever use of 
tobacco increased the risk of HCC (Table 3). Among individuals with baseline 
cirrhosis, only HBV and HCV coinfection were associated with HCC (Appendix 4). 
Results were similar in analyses accounting for the competing risk of death 
(data not shown) and using 360-day and 540-day lags for HIV RNA and CD4+ cell 
percentage (Appendix 5). Similar findings were observed when analyses were 




























individuals, though results for some risk factors did not achieve statistical 
significance given the smaller sample sizes in these groups. There were too few HCC 
events (n=17) among HIV-infected patients without viral hepatitis to permit analysis.
When possible fatty liver disease was evaluated, patients who had both baseline 
obesity and diabetes had a higher risk of HCC than those who did not (2.32 [1.19-
4.52]; Appendix 8). Longer consecutive months with CD4+ percentage <14% did 
not increase HCC risk (≥12 months: 1.02 [0.69-1.51]; 1-11 months: 1.15 [0.65-2.05])
compared to those with ≥14% throughout follow-up. 
In exploratory analyses, after adjustment for HIV RNA and traditional risk 
factors, the risk of HCC was not increased with lower time-updated CD4+/CD8+ 
ratio among either individuals with baseline cirrhosis (1.000 [0.999-1.001] per 0.1 
unit decrease) or without cirrhosis (0.991 [0.981-1.002] per 0.1 unit decrease).
DISCUSSION
To our knowledge, this is the largest study to evaluate HIV-related and 
traditional risk factors for HCC among HIV-infected patients, and the first to 
examine such determinants by baseline cirrhosis status. We stratified our analyses 
by baseline cirrhosis status to account for the possibility that risk factors for HCC 
might vary by the presence of cirrhosis. Among patients without baseline cirrhosis, 
time-updated detectable HIV (≥500 copies/mL), higher HIV RNA (particularly 
≥10,000 copies/mL), and ≥12 months of detectable HIV increased risk of HCC, 
independent of traditional risk factors. Older age, HBV, HCV, diabetes, alcohol 
dependence/abuse, and tobacco use, which are traditional risk factors for HCC, also 
increased HCC risk in this group. The risk of HCC was particularly high in those with 
both obesity and diabetes. Among patients with baseline cirrhosis, only HBV and 




























percentage was not associated with increased risk of HCC regardless of cirrhosis 
status.
Our study is the first to find that higher level and longer duration of HIV 
viremia contribute to HCC risk. HIV viremia could contribute to HCC by accelerating 
hepatic fibrosis progression to cirrhosis or by directly promoting 
hepatocarcinogenesis via immune dysregulation, oxidative stress, hepatocyte 
apoptosis, and/or depletion of CD4+ cells in the gastrointestinal tract with resultant 
microbial translocation.32-34 We have previously shown that suppression of HIV 
viremia can delay onset of cirrhosis.21 Our findings suggest that achieving and 
maintaining HIV suppression could mitigate the risk of HCC.
Three prior studies found no association between HIV RNA and risk of HCC, but
none stratified analyses by baseline cirrhosis status. One study of 31,576 HIV-
infected patients in the VA HIV Clinical Case Registry from 1985-2010 found that 
longer percentage of time with undetectable HIV RNA (<500 copies/mL) did not 
decrease HCC risk.5 A follow-up study among 8,563 HIV/HCV-coinfected patients in 
this registry similarly found no association between duration of undetectable HIV 
RNA and HCC.6 However, both analyses included cirrhosis as a covariate in 
multivariable models. Since cirrhosis is in the causal pathway to HCC, controlling for 
cirrhosis could have adjusted away associations between HIV suppression and HCC. 
A third study among 42,441 HIV-infected patients in the VACS from 1999-2015 found
that neither early (≤2 years) nor long-term (>2 years) HIV suppression decreased 
rates of HCC compared to 104,712 demographically similar uninfected persons.7 
However, this analysis did not stratify results by baseline cirrhosis status.
Contrary to previous studies,6,8-12 we found that HIV-related 



























with an increased risk of HCC. Notably, those prior studies evaluated the risk of HCC
associated with lower absolute CD4+ count. Indeed, when we evaluated 
associations between absolute CD4+ count and HCC in our cohort, CD4+ counts 
<200 cells/mm3 increased HCC risk. However, absolute CD4+ count may decrease 
during cirrhosis as a result of portal hypertension-induced splenic sequestration, but
CD4+ percentage remains unchanged during cirrhosis.13 Our results suggest that 
HIV-related immunosuppression is not an important contributor to HCC risk and that
the findings of prior analyses likely reflected the effect of liver fibrosis progression 
on absolute CD4+ count.
Interestingly, 32.8% of patients with HCC in our study did not have evidence 
of cirrhosis based on review of medical records within one year prior to cancer 
diagnosis. HCC can develop in the absence of advanced hepatic fibrosis in chronic 
HBV infection or non-alcoholic fatty liver disease.35,36 Further research is needed to 
determine how frequently HCC occurs in the absence of cirrhosis in HIV and if this 
differs from uninfected persons.
The study has several potential limitations. First, we might have 
underestimated cirrhosis, since this condition is clinically silent. However, cirrhosis 
was identified using validated diagnoses, and the negative predictive value of this 
definition exceeded 99%.23,24 Second, we were unable to determine fatty liver 
disease, since this diagnosis requires liver imaging or biopsy to confirm. We classified
possible fatty liver disease by baseline presence of both obesity and diabetes. Future 
studies should evaluate the effect of fatty liver disease on HCC in HIV. Third, we did 
not evaluate the risk of HCC with antiretroviral drugs, particularly those associated 
with hepatotoxicity,37 or viral hepatitis treatments. Additional research should 



























was predominantly comprised of male US Veterans, but the study included 867 HIV-
infected women.
In conclusion, among HIV-infected patients without cirrhosis, higher HIV RNA 
and longer duration of HIV viremia, in addition to HBV and HCV coinfection, were 
important determinants of HCC, independent of traditional risk factors. HIV-related 
immunosuppression, determined by CD4+ cell percentage, was not associated with 
increased risk of HCC. This study provides the strongest evidence to date that HIV 
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Figure 1. Pathway to development of hepatocellular carcinoma (HCC). The figure shows the 
contributions of the key modifiable determinants of HCC, including traditional risk factors 
(blue) and the hypothesized HIV-related determinants in this study (red). Both chronic 
hepatitis B virus (HBV) infection and HIV viremia could increase the risk of HCC by inducing 


















Median age (years, IQR) 46 (39-53) 46 (39-53) 49 (44-55)
Male sex 34,792 (97.6) 34,032 (97.6) 760 (98.3)
Race/ethnicity
Black 17,069 (47.9) 16,750 (48.0) 319 (41.3)
Caucasian 13,859 (38.9) 13,522 (38.8) 337 (43.6)
Hispanic 2,720 (7.6) 2,632 (7.5) 88 (11.4)
Other/Unknown 2,011 (5.6) 1,982 (5.7) 29 (3.8)
Body mass index
Underweight (<18.50 kg/m2) 837 (2.3) 819 (2.3) 18 (2.3)
Normal (18.50-24.99 kg/m2) 14,083 (39.5) 13,768 (39.5) 315 (40.8)
Overweight (25.00-29.99 kg/m2) 11,415 (32.0) 11,184 (32.1) 231 (29.9)
Obesity (30.00-34.99 kg/m2) 3,882 (10.9) 3,789 (10.9) 93 (12.0)
Morbid obesity (35.00 kg/m2) 1,323 (3.7) 1,299 (3.7) 24 (3.1)
Missing weight and/or height 4,119 (11.6) 4,027 (11.5) 92 (11.9)
Diabetes mellitus 3,308 (9.3) 3,150 (9.0) 158 (20.4)
History of alcohol dependence/abuse 10,538 (29.6) 10,064 (28.8) 474 (61.3)
History of injection/non-injection drug 
use
16,235 (45.5) 15,781 (45.2) 454 (58.7)
Tobacco use
Never 9,533 (26.7) 9,393 (26.9) 140 (18.1)
Ever‡ 24,707 (69.3) 24,158 (69.2) 549 (71.0)
Unknown 1,419 (4.0) 1,335 (3.8) 84 (10.9)
Hepatitis C virus coinfection§
Detectable HCV RNA or genotype 11,392 (31.9) 10,940 (31.4) 452 (58.5)
Ever treated with HCV antiviral 1,354 (11.9) 1,304 (11.9) 50 (11.1)
HCV antibody+/HCV RNA- 1,055 (3.0) 1,020 (2.9) 35 (4.5)
HCV antibody- 21,472 (60.2) 21,247 (60.9) 225 (29.1)
Never tested 1,740 (4.9) 1,679 (4.8) 61 (7.9)
Hepatitis B virus coinfection||
HBsAg+ 1,981 (5.6) 1,873 (5.4) 108 (14.0)
Ever treated with HBV-active 
antiretroviral
1,840 (92.9) 1,748 (93.3)  92 (85.2)
HBsAg- 31,712 (88.9) 31,096 (89.1) 616 (79.7)
Never tested 1,966 (5.5) 1,917 (5.5) 49 (6.3)
HIV RNA
Median (log10 cells/mm3, IQR) 3.2 (1.7-4.6) 3.2 (1.7-4.6) 3.0 (1.7-4.6)
500 copies/mL 20,216 (56.7) 19,791 (56.7) 425 (55.0)
CD4+ cell percentage
Median (%, IQR) 22 (14-31) 22 (14-31) 22 (14-31)
≥28% 11,776 (33.0) 11,530 (33.1) 246 (31.8)










Median (IQR) 0.40 (0.21-0.69) 0.40 (0.21-0.69) 0.42 (0.21-
0.70)
<1.0 31,553 (88.5) 30,879 (88.5) 674 (87.2)
Median alanine aminotransferase (U/L) 31 (21-47) 30 (21-47) 41 (27-71)
Not assessed at baseline 2,362 (6.6) 2,338 (6.7) 24 (3.1)
Median aspartate aminotransferase 
(U/L)










Not assessed at baseline 1,987 (5.6) 1,964 (5.6) 23 (3.0)
Platelet count (x 106/L)
150,000 30,570 (85.7) 30,194 (86.6) 376 (48.6)
<150,000 4,812 (13.5) 4,420 (12.7) 392 (50.7)
Not assessed at baseline 277 (0.8) 272 (0.8) 5 (0.6)
Median baseline FIB-4 (IQR) 1.18 (0.81-1.78) 1.17 (0.81-1.74) 3.00 (1.58-
5.82)
Unable to be calculated at baseline 3,325 (9.3) 3,290 (9.4) 35 (4.5)
On antiretroviral therapy 24,506 (68.7) 23,980 (68.7) 526 (68.0)
Most common baseline antiretroviral 
regimens¶
Efavirenz/tenofovir/emtricitabine 3,639 (14.8) 3,565 (14.9) 74 (14.1)
Efavirenz/zidovudine/lamivudine 1,764 (7.2) 1,738 (7.2) 26 (4.9)









Nelfinavir/stavudine/lamivudine 888 (3.6) 863 (3.6) 25 (4.8)
Indinavir/stavudine/lamivudine 725 (3.0) 708 (3.0) 17 (3.2)
Nevirapine/zidovudine/lamivudine 663 (2.7) 652 (2.7) 11 (2.1)
Efavirenz/stavudine/lamivudine 611 (2.5) 590 (2.5) 21 (4.0)
Abbreviations: HBsAg=hepatitis B surface antigen; HBV=hepatitis B virus; HCV=hepatitis C virus; 
HIV=human immunodeficiency virus; IQR=interquartile range; RNA=ribonucleic acid
* Results reported as n (%) unless otherwise specified.
† Cirrhosis defined as any diagnosis of compensated or decompensated cirrhosis prior to the start of follow-
up.
‡ Ever tobacco use includes current and prior tobacco use.
§ Hepatitis C virus coinfection defined as positive quantitative HCV RNA (absolute value determinable or 
not), positive qualitative HCV RNA, or quantifiable HCV genotype at baseline or during follow-up.
|| Hepatitis B virus coinfection defined as positive HBV surface antigen at baseline or during follow-up.













Table 2. Characteristics of patients with incident hepatocellular carcinoma, stratified by 











Median age at diagnosis (years, IQR) 56.4 (51.3-61.1) 57.5 (51.3-61.8) 56.0 (51.3-60.9)
Median time to diagnosis (years, IQR) 7.2 (3.9-10.6) 6.3 (3.5-10.3) 7.4 (4.2-11.1)
Male sex 299 (99.0) 99 (100.0) 200 (98.5)
Race/ethnicity
Black 159 (52.6) 62 (62.6) 97 (47.8)
Caucasian 97 (32.1) 24 (24.2) 73 (36.0)
Hispanic 37 (12.3) 10 (10.1) 27 (13.3)
Other/Unknown 9 (3.0) 3 (3.0) 6 (3.0)
Body mass index
Underweight (<18.50 kg/m2) 25 (8.3) 16 (16.2) 9 (4.4)
Normal (18.50-24.99 kg/m2) 128 (42.4) 47 (47.5) 81 (39.9)
Overweight (25.00-29.99 kg/m2) 102 (33.8) 25 (25.3) 77 (37.9)
Obesity (30.00-34.99 kg/m2) 34 (11.3) 9 (9.1) 25 (12.3)
Morbid obesity (35.00 kg/m2)







Diabetes mellitus 94 (31.1) 24 (24.2) 70 (34.5)
History of alcohol dependence/abuse 191 (63.2) 61 (61.6) 130 (64.0)
History of injection/non-injection drug use 246 (81.5) 81 (81.8) 165 (81.3)
Tobacco use
    Never 40 (13.2) 10 (10.1) 30 (14.8)
    Ever† 262 (86.8) 89 (89.9) 173 (85.2)
Hepatitis C virus coinfection‡
Detectable HCV RNA or genotype 250 (82.8) 79 (79.8) 171 (84.2)
HCV antibody+/HCV RNA- 5 (1.7) 1 (1.0) 4 (2.0)
HCV antibody- 39 (12.9) 15 (15.2) 24 (11.8)
Never tested 8 (2.6) 4 (4.0) 4 (2.0)
Hepatitis B virus coinfection§
    HBsAg+ 57 (18.9) 17 (17.2) 40 (19.7)
HBsAg- 236 (78.1) 79 (79.8) 157 (77.3)
Never tested 9 (3.0) 3 (3.0) 6 (3.0)
Median HIV RNA (log10 copies/mL, IQR) 1.7 (1.7-2.6) 1.7 (1.7-2.6) 1.7 (1.7-2.7)
CD4 percentage
Median (%, IQR) 26 (17-35) 26 (14-35) 26 (18-35)
≥28% 135 (44.7) 42 (42.4) 93 (45.8)
14-27.99% 120 (39.7) 35 (35.4) 85 (41.9)
<14%  47 (15.6) 22 (22.2) 25 (12.3)
CD4:CD8 ratio
Median (IQR) 0.57 (0.31-0.93) 0.52 (0.26-0.98) 0.59 (0.33-0.91)
<1.0 239 (79.1) 77 (77.8) 162 (79.8)
Median alanine aminotransferase (U/L, IQR) 54 (36-79) 52 (35-74) 57 (36-79)
Not assessed within 360 days prior to HCC 
diagnosis
2 (0.7) 0 (0.0) 2 (1.0)
Median aspartate aminotransferase (U/L, 
IQR)
68 (44-101) 61 (38-95) 73 (47-104)
Not assessed within 360 days prior to HCC 
diagnosis
1 (0.3) 0 (0.0) 1 (0.5)















    <1.45
    1.45-3.25
    >3.25













On antiretroviral therapy 229 (75.8) 77 (77.8) 152 (74.9)
Ever dideoxynucleoside analogue use¶ 207 (68.5) 74 (74.7) 133 (65.5)
Abbreviations: HBsAg=hepatitis B surface antigen; HCC=hepatocellular carcinoma; HCV=hepatitis C virus; 
HIV=human immunodeficiency virus; IQR=interquartile range; NRTI=nucleoside reverse transcriptase 
inhibitors; RNA=ribonucleic acid
* Results reported as n (%) unless otherwise specified.
† Ever tobacco use includes current and prior tobacco use.
‡ Hepatitis C virus coinfection defined as positive quantitative HCV RNA (absolute value determinable or not), 
positive qualitative HCV RNA, or quantifiable HCV genotype at baseline or during follow-up.
§ Hepatitis B virus coinfection defined as positive HBV surface antigen at baseline or during follow-up.
|| FIB-4 was calculated using current age and most recent alanine aminotransferase, aspartate 
aminotransferase, and platelet count within 360 days prior to HCC diagnosis.













Table 3. Factors associated with incident hepatocellular carcinoma among HIV-infected patients in the Veterans 
Aging Cohort Study (October 1, 1999-September 30, 2015) without a baseline diagnosis of cirrhosis (n=34,886; 270 
hepatocellular carcinoma events).


























White Reference Reference Reference Reference Reference















Baseline body mass index






Normal (18.50-24.99 kg/m2) Reference Reference Reference Reference Reference










1.01 (0.65-1.56) 1.01 (0.65-
1.56)







Hepatitis B virus coinfection
   HBsAg-
   HBsAg+
































Hepatitis C virus coinfection
HCV antibody- Reference Reference Reference Reference Reference













































































    Never Reference Reference Reference Reference Reference







Time-updated HIV RNA (per 1.0 log10
copies/mL)
1.26 (1.14-1.39) 1.25 (1.12-
1.40)
- - -
Current HIV RNA ≥500 copies/mL

























HIV RNA always <500 copies/mL Reference - - Reference
1-11 months of HIV RNA ≥500 copies/
mL
1.63 (1.07-2.49) - - 1.46 (0.94-
2.26)
≥12 months of HIV RNA ≥500 
copies/mL
1.55 (1.10-2.18) - - 1.47 (1.02-
2.11)
Abbreviations: CI=confidence interval; HBsAg=hepatitis B surface antigen; HBV=hepatitis B virus; HCV=hepatitis C virus; HIV=human 
immunodeficiency virus; HR=hazard ratio; RNA=ribonucleic acid
* Model #1 includes continuous values of HIV RNA as log10 copies/mL
† Model #2 includes current HIV RNA ≥500 copies/mL
‡ Model #3 includes current categories of HIV RNA ≥500 copies/mL
§ Model #4 includes consecutive months of HIV RNA ≥500 copies/mL
|| Ever tobacco use includes current and prior tobacco use
¶ p for trend=0.01.
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